Agomelatine reviews converge on one finding: it works for major depression, but modestly. Across placebo-controlled trials, agomelatine beats placebo by roughly 2 to 3 points on the Hamilton Depression Rating Scale (HAM-D), with response rates near 50 to 55 percent versus 35 to 40 percent for placebo. Its real distinction is tolerability. It produces almost no sexual dysfunction (under 2 percent in trials) and minimal weight change, but it carries a liver-monitoring requirement that most reviews underplay: roughly 1 in 100 patients shows a clinically meaningful transaminase rise. It is a reasonable second-line option, not a first-line miracle.
The mechanism behind agomelatine reviews
Agomelatine is not a selective serotonin reuptake inhibitor. It has no meaningful affinity for the serotonin transporter. Instead, it works through two receptors, and the way those two receptors interact explains most of what the reviews describe.
The drug is a potent agonist at melatonin MT1 and MT2 receptors. Melatonin receptors sit in the suprachiasmatic nucleus, the brain's master clock. Agomelatine binds them with an affinity roughly 100 times that of endogenous melatonin, per in vitro binding data. This is thought to resynchronize circadian rhythms that depression disrupts.
The second mechanism is a 5-HT2C receptor antagonist effect. Serotonin 2C receptors normally inhibit the release of dopamine and norepinephrine in the prefrontal cortex. Blocking them disinhibits that release. In plain terms: agomelatine restores the body clock while loosening a brake on dopamine and norepinephrine.
The non-obvious part is the timing. The half-life is only 1 to 2 hours, yet the clinical effect builds over weeks. This argues that the drug is not acting directly but is retraining the circadian system, which then takes time to stabilize. That hypothesis, not confirmed mechanism, is why dosing at bedtime matters more than plasma levels suggest.
What the trials show, in numbers
The evidence base is 8 short-term placebo-controlled trials plus several long-term relapse-prevention studies. Most ran 6 to 8 weeks. The consistent finding is a separation from placebo that is statistically significant but clinically modest.
| Measure | Agomelatine (25-50 mg) | Placebo | Interpretation |
|---|---|---|---|
| HAM-D change from baseline | 12 to 14 points | 9 to 11 points | 2 to 3 point advantage |
| Response rate (50% reduction) | 50-55% | 35-40% | Real but not dramatic |
| Remission rate | 30-35% | 20-25% | Roughly 10 points |
| Sexual dysfunction | under 2% | 1-2% | Essentially no signal |
| Weight gain over 8 weeks | under 1 lb | under 1 lb | Negligible difference |
| Discontinuation for side effects | 4-6% | 3-4% | Very close to placebo |
The comparison to standard antidepressants is where the number reconciliation matters. Reviews often quote a 2 to 3 point HAM-D advantage over placebo as underwhelming. But SSRIs in the same meta-analytic framework show a similar 2 to 3 point advantage. The distinction is tolerability, not raw efficacy.
One quantified comparison rarely appears in top results: agomelatine's 50 mg dose shows a dose-response curve that flattens between 25 mg and 50 mg. Trials found the 50 mg dose adds about 1 extra HAM-D point over 25 mg, which is why European regulators approved both doses but the marginal gain is small.
Side effects and the liver question
Most agomelatine reviews are too soft on the liver. Agomelatine causes serum transaminase elevations of more than three times the upper limit of normal in roughly 1 to 2 percent of patients. That is the single most important safety caveat.
Per the European Medicines Agency's 2014 review, patients with pre-existing liver impairment or transaminase elevation above three times normal should not take it. Liver function tests are required at baseline, around week 3, around week 6, and again around week 12 and week 24 in the product labeling. Stopping the drug usually normalizes enzymes within weeks.
The other side effects are comparatively mild. Headache occurs in about 14 percent, nausea in about 8 percent, and dizziness in about 5 percent. These are close to placebo rates and usually fade within the first two weeks.
Red flags that require stopping and calling a clinician:
- Dark urine or pale stools, which can signal cholestasis
- Yellowing of the eyes or skin
- Right upper abdominal pain that persists
- Transaminases rising above three times normal on repeat testing
- A new combination of agitation and insomnia suggesting activation
The timeline of a fair trial
Agomelatine reviews frequently skip how long a person must wait. The drug behaves differently from SSRIs in one key respect: sleep improves first, mood second. This is consistent with its melatonin receptor action.
| Timeframe | What typically happens |
|---|---|
| Week 1 | Sleep onset and quality may improve; mood largely unchanged |
| Week 2 | Early mood change possible; side effects like headache peak |
| Week 3-4 | Liver function testing due; responders begin to separate |
| Week 6 | Full antidepressant effect usually detectable; second liver check |
| Week 8 | Standard trial endpoint; non-responders often switch |
| Week 12 | Continued liver monitoring; decision on long-term use |
| Month 6-12 | Relapse-prevention benefit established in trials; monitoring tapers |
One non-obvious detail: because the drug is short-acting, an abrupt stop rarely causes the discontinuation syndrome that plagues SSRIs like paroxetine. Reviews note this as an advantage for people who struggle to taper.
Where agomelatine reviews overstate the case
The most common overstatement is presenting agomelatine as a first-line equal to SSRIs. It is not. Meta-analyses, including a 2019 analysis in the journal Psychotherapy and Psychosomatics, concluded that agomelatine's efficacy sits at the lower end of the antidepressant range. It is typically used second-line.
A second misconception is that the melatonin mechanism makes it a sleep aid. It is not a hypnotic. It is an antidepressant with a circadian rationale. Reviews that market it as a sleep drug blur that line.
A third caveat that fewer reviews mention: agomelatine is not approved in the United States. It is available in Europe, Australia, and parts of Asia. Anyone reading US-based reviews is reading about a drug they cannot get through a standard pharmacy there. This matters for interpreting trial populations, which are largely European.
Agomelatine vs other antidepressants
The table below compares agomelatine to the two most commonly discussed alternatives in reviews, based on head-to-head and meta-analytic data.
| Feature | Agomelatine | SSRIs (e.g., sertraline) | SNRIs (e.g., venlafaxine) |
|---|---|---|---|
| HAM-D advantage over placebo | 2-3 points | 2-3 points | 2-4 points |
| Sexual dysfunction | under 2% | 30-50% | 40-60% |
| Weight gain | under 1 lb | 2-5 lb | 4-8 lb |
| Discontinuation syndrome | minimal | notable | marked |
| Liver monitoring | required | not routine | not routine |
| Sleep benefit | early, built-in | variable | variable |
| Availability in US | no | yes | yes |
| Cost per month (Europe) | USD 30-50 | USD 10-30 | USD 20-60 |
The comparison shows why agomelatine reviews center on tolerability. It loses on efficacy and convenience (liver tests) but wins on the side effects people most often abandon SSRIs to avoid.
What to actually do with this information
If a clinician is considering agomelatine, the practical steps are concrete. Get baseline liver enzymes first. If they are already elevated, this is the wrong drug. Start at 25 mg at bedtime and give it 6 weeks before judging mood, while watching sleep in the first 10 days as an early signal.
Then follow the testing schedule. Week 3 and week 6 transaminase checks are not optional; they are what separates safe use from the 1 to 2 percent who develop meaningful liver injury. If enzymes rise above three times normal, stop.
Be honest about expectations. A 2 to 3 point HAM-D advantage is real but modest. If the primary goal is avoiding sexual side effects or weight gain, agomelatine is a strong candidate. If the primary goal is maximum efficacy in severe depression, an SSRI or SNRI still leads.
Limits of the evidence
The honest limitation is that agomelatine's trial base is smaller and more homogeneous than the SSRI literature. Most trials enrolled European adults with moderate depression, so data in severe depression, adolescents, and non-European populations is thinner.
Several trials were also small, and the effect size has varied across them. A 2018 network meta-analysis grouped agomelatine with several other agents in the modest-efficacy tier, a spot that reviews citing only the best trials tend to omit. The thyroid and liver interactions are well characterized, but long-term data past two years is sparse.
In plain terms: agomelatine reviews that market it as either a wonder drug or a disappointment are both wrong. It is a modest, well-tolerated option with one monitoring burden. That is a fair reading of two decades of data, and it is the one the trials actually support.